ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Niraparib, Temozolomide and Irinotecan
ACCRUAL STATUS: Not Recruiting

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Rashmi Chugh, MD
University of Michigan

Sandra Strauss, MBBS, PhD
University College London, Cancer Institute

CLINICALTRIALS.GOV IDENTIFIER: NCT02044120

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: